New Treatment Options for Prostate Cancer

Segment 7 - The Payer's Role and Future Trends
September 12, 2013 – 
Panelists all agree that there needs to be evidence and guidelines for both payers and providers. There are not enough resources to try every drug on every patient. Although it will be costly, there needs to be evidence on putting these drugs together as combinations.
Segment 6 - Personalized Medicine
September 12, 2013 – 
Dr Crawford said that in order to pick the appropriate treatment for a diagnosed patient with prostate cancer, it is important to think outside of the box. The National Comprehensive Cancer Network (NCCN) and the American Urological Association (AUA) offer castration-resistant prostate cancer (CRPC) guidelines that serve as the best guideline for payers.
Segment 5 - Emerging Agents
September 12, 2013 – 
It is an exciting time for prostate cancer due to the growth in new treatments. Dr George said that it is, in fact, both exciting and daunting to have all of these new agents being developed. Currently, there is a shortage in data for practitioners in using the new agents in sequence or combination.
Segment 4 - Advances and Challenges in Prostate Cancer
September 12, 2013 – 
In this segment of the panel discussion, Dr Fendrick asks the panelists if there is now a sense of optimism in reducing the mortality and quality gaps in prostate cancer treatment due to targeted screening and new molecular diagnostics, and immunotherapies.
Segment 3 -Managing Treatment Options and Shared Decision Making
September 12, 2013 – 
Dr George notes that in an ideal world a multidisciplinary clinic would not be necessary. Multidisciplinary clinics deliver the tools to practitioner to make the best decisions for their patients.
Segment 2 - Team-Based Approach to Treatment
September 12, 2013 – 
In this segment, panelists examine prostate cancer treatment as a model for team-based approach. Panelists agree that there is a need for a multidisciplinary approach to care. There
Segment 1 - Introduction and Treatment Options
September 12, 2013 – 
Dr Mark Fendrick opens the discussion by introducing panelists and asking them to discuss the controversy surrounding prostate cancer screening. Panelists address United States Preventive Services Task Force (USPSTF) versus American Urological Association (AUA) guidelines and recommendations.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome to the new and improved, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!